Cybin (OTCMKTS:CYBN) Stock Price Down 2%

Cybin Inc. (OTCMKTS:CYBN) traded down 2% on Thursday . The company traded as low as $0.36 and last traded at $0.37. 1,714,145 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 5,246,800 shares. The stock had previously closed at $0.38.

Cybin Price Performance

The company has a market capitalization of $151.19 million, a PE ratio of -1.75 and a beta of 0.43. The business has a 50-day moving average of $0.39 and a 200 day moving average of $0.43.

Cybin (OTCMKTS:CYBN) last posted its earnings results on Wednesday, February 14th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). As a group, research analysts anticipate that Cybin Inc. will post -0.19 EPS for the current year.

Institutional Investors Weigh In On Cybin

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CYBN. Virtu Financial LLC grew its stake in shares of Cybin by 104.0% during the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after buying an additional 46,129 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Cybin by 926.4% during the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock valued at $52,000 after buying an additional 98,596 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Cybin by 370.6% during the first quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock valued at $61,000 after buying an additional 58,771 shares during the last quarter. Belpointe Asset Management LLC grew its stake in shares of Cybin by 21.5% during the first quarter. Belpointe Asset Management LLC now owns 313,705 shares of the company’s stock valued at $121,000 after buying an additional 55,600 shares during the last quarter. Finally, Penserra Capital Management LLC grew its stake in shares of Cybin by 55.8% during the first quarter. Penserra Capital Management LLC now owns 407,309 shares of the company’s stock valued at $223,000 after buying an additional 145,929 shares during the last quarter. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.